A Clinical Study to Evaluate Safety of the ExAblate 2100 UF V2 System in the Treatment of Symptomatic Uterine Fibroids

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The first magnetic resonance-guided focused ultrasound (MRgFUS) treatment of uterine fibroid using the ExAblate 2000 system was performed in 2001. Since then, more than 5000 treatments were done in more than 60 different hospitals around the world. The experience accumulated in this novel treatment was collected by InSightec and implemented into software and hardware updates, clinical tips and guidelines, all aimed to improve the clinical results and their durability, while maintaining a high level of safety.

Based on extensive clinical experience and our internal research and development effort goals toward continuous improvement in ExAblate treatment safety and performance, limited changes have been made to the current ExAblate system. This modified ExAblate system version is designated as the ExAblate 2100 UF V2 system.

The modifications are believed to improve system's friendliness to the user, without introducing new risks or other issues of safety of the device, and should not have any negative impact on the safety or technical efficacy of the treatments for patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids

NCT01285960

Uterine Fibroids

COMPLETED NA

Study to Evaluate the Safety and Effectiveness of MRgFUS Compared With Myomectomy for the Treatment of Uterine Fibroids

NCT01328067

Uterine Fibroids Bleeding Pelvic Pain

WITHDRAWN NA

MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation

NCT00295217

Uterine Fibroids Uterine Leiomyomas

COMPLETED PHASE3

Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids

NCT00131365

Leiomyoma

COMPLETED NA

MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication

NCT00365989

Uterine Leiomyoma Uterine Fibroids

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Fibroids Bleeding Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exablate 2100

MR Guided Focused Ultrasound treatment

Group Type EXPERIMENTAL

Exablate 2100

Intervention Type DEVICE

MR guided focused ultrasound

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exablate 2100

MR guided focused ultrasound

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women age 18 or older
2. Symptomatic uterine fibroids, defined as those resulting in scores of 21 or higher, based on patient responses to questions 1-8 of the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL).
3. Women who have given written informed consent
4. Women who are able and willing to attend all study visits
5. Patient is pre or peri-menopausal (within 12 months of last menstrual period)
6. Able to communicate sensations during the ExAblate procedure.
7. Uterine fibroids, which are device accessible
8. Fibroid(s) clearly visible on non-contrast MRI.
9. Fibroid(s) enhances on MR contrast imaging

Exclusion Criteria

1. Women who are pregnant, as confirmed by serum/urine test at time of screening, or urine pregnancy test on the day of treatment
2. Uterine size \> 24 weeks
3. Patients who are breast-feeding
4. Patients with active pelvic inflammatory disease (PID).
5. Patients with active local or systemic infection
6. Contraindication for MRI Scan:

1. Severe claustrophobia that would prevent completion of procedure in the MR unit
2. Weight greater than 250 IBS (113Kg)
3. Implanted ferromagnetic materials and/or devices contraindicated for MR scan
4. Known intolerance to MRI contrast agent (e.g. Gadolinium or Magnevist)
5. Any other contraindication for MRI Scan
7. Extensive abdominal scarring in the beam path
8. Dermoid cyst obstructing the treatment path.
9. Known pelvic malignant or pre-malignant conditions
10. Intrauterine device (IUD) anywhere in the treatment path

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No